

C型慢性肝炎に対するペグインターフェロン+リバビリン併用療法の有効性を規定する*IL28B*(インターフェロンλ)領域の遺伝子多型(SNPs)





Genome-wide association of *IL28B* with response to pegylated interferon- $\alpha$  and ribavirin therapy for chronic hepatitis C

Yasuhito Tanaka<sup>1,18</sup>, Nao Nishida<sup>2,18</sup>, Masaya Sugiyama<sup>1</sup>, Masayuki Kurosaki<sup>3</sup>, Kentaro Matsuura<sup>1</sup>, Naoya Sakamoto<sup>4</sup>, Mina Nakagawa<sup>4</sup>, Masaaki Korenaga<sup>5</sup>, Keisuke Hino<sup>5</sup>, Shuhei Hige<sup>6</sup>, Yoshito Ito<sup>7</sup>, Eiji Mita<sup>8</sup>, Eiji Tanaka<sup>9</sup>, Satoshi Mochida<sup>10</sup>, Yoshikazu Murawaki<sup>11</sup>, Masao Honda<sup>12</sup>, Akito Sakai<sup>12</sup>, Yoichi Hiasa<sup>13</sup>, Shuhei Nishiguchi<sup>14</sup>, Asako Koike<sup>15</sup>, Isao Sakaida<sup>16</sup>, Masatoshi Imamura<sup>17</sup>, Kiyooki Ito<sup>17</sup>, Koji Yano<sup>17</sup>, Naohiko Masaki<sup>17</sup>, Fuminaka Sugauchi<sup>1</sup>, Namiki Izumi<sup>3</sup>, Katsushi Tokunaga<sup>2</sup> & Masashi Mizokami<sup>1,17</sup>

**Tanaka Y, Mizokami M., et al. Nature Genetics 2009**

# IL28B関連の最近の話題

## PEG-IFN/RBV併用療法の効果とIL28B遺伝子多型



# IL28Bアレル別のHCV-RNA陰性化率

